ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/breast/metastatic/endocrine-refractory/first-line
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Breast / Breast - Metastatic / Endocrine refractory / First line
5
trial(s) found.
NCT07085767
Advanced
Phase 3
Recruiting
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the
First-Line
Treatment of ER+, HER2- Advanced Breast Cancer (
OPERA-02
)
CDK4/6 inhibitor
aromatase inhibitor
complete estrogen receptor antagonist
Breast cancer
ER-positive breast cancer
HER2-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06757634
Advanced
Phase 3
Recruiting
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as
First-Line
Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer (
CELC-G-302
)
pan-PI3K/mTORC1/mTORC2 inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4215 - Southport - ICON Cancer Care
SA
5000 - South Australia - GenesisCare St Andrews Hospital
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06380751
Advanced
Phase 3
Recruiting
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the
First-Line
Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01) (
EvoPAR-BR01
)
PARP1-selective inhibitor
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT05894239
Advanced
Phase 3
Recruiting
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After
First Line
Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (
INAVO122
)
PI3K alpha inhibitor
placebo
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NA
NA
ACTRN12622000016730
Advanced
Phase 1
Recruiting
Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously
untreated
HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study (
HER2Pro-1B
)
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
antihistamine
taxane
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Recruitment Country and State
NSW (5)
QLD (3)
VIC (3)
WA (3)
SA (2)
Phase
Phase 1 (1)
Phase 3 (4)
Trial Type
Advanced (5)
Cancer Therapy Class
CDK4
60%
CDK6
60%
ER
60%
oestrogen axis
60%
PI3Kalpha
40%
PI3K
20%
mTOR
20%
mTORC1
20%
mTORC2
20%
PARP
20%
PARP1-selective
20%
ERBB2
20%
Facility
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (3)
3168 - Clayton - Monash Medical Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4215 - Southport - ICON Cancer Care (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
NA
4102 - Woolloongabba - Princess Alexandra Hospital (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
Breast adenocarcinoma
ER-positive breast cancer
HER2-negative breast cancer
HR-positive breast cancer
HER2-positive breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy